Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Vandetanib is a potent VEGFR-2 inhibitor (IC50 = 0.04 μM), and inhibitor of EGFR (IC50 = 0.5 μM). Vandetanib potently inhibits (IC50 = 100 nM) RET oncoprotein activity in human thyroid cancer. Vandetanib displays anti-angiogenic properties in human nasopharyngeal carcinoma in mice model. Vandetanib is orally available and effective in vivo.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 475.36. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||4.21 mL||21.04 mL||42.07 mL|
|2.5 mM||0.84 mL||4.21 mL||8.41 mL|
|5 mM||0.42 mL||2.1 mL||4.21 mL|
|25 mM||0.08 mL||0.42 mL||0.84 mL|
References are publications that support the biological activity of the product.
Carlomagno et al (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer res. 62 7284 PMID: 12499271
Cui et al (2015) Resonance imaging for monitoring the early response to ZD6474 from nasopharyngeal carcinoma in nude mouse. Sci.Rep. 5 16389 PMID: 26574153
Ancker et al (2019) Multikinase inhibitor treatment in thyroid cancer. Int.J.Mol.Sci. 21 10 PMID: 31861373
Hennequin et al (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J.Med.Chem. 45 1300 PMID: 11881999
If you know of a relevant reference for Vandetanib, please let us know.
Keywords: Vandetanib, Vandetanib supplier, Potent, inhibitors, inhibits, VEGFR-2, Vascular, Endothelial, Growth, Factors, Receptors, KDR, Flk1, EGFR, epidermal, growth, factor, receptor, anticancer, RET, VEGFR, 7497, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for Vandetanib. Do you know of a great paper that uses Vandetanib from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Vandetanib and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.